Trials / Completed
CompletedNCT00024258
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced neuroblastoma or other solid tumors.
Detailed description
OBJECTIVES: * Determine the response rates of patients with advanced neuroblastoma or other pediatric solid tumors treated with arsenic trioxide. * Determine the toxicity of this drug in these patients. OUTLINE: Patients are stratified according to type of disease (neuroblastoma with progressive disease vs neuroblastoma with stable refractory disease vs other solid tumor). Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2-3 months for 1 year and then annually thereafter.
Conditions
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- Kidney Cancer
- Liver Cancer
- Neuroblastoma
- Ovarian Cancer
- Retinoblastoma
- Sarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | arsenic trioxide |
Timeline
- Start date
- 2001-03-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2003-01-27
- Last updated
- 2015-11-25
- Results posted
- 2015-11-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00024258. Inclusion in this directory is not an endorsement.